Justine Benevent | Pharmaceutical Science | Best Scholar Award

Posted on by ScienceFather

Dr. Justine Benevent | Pharmaceutical Science | Best Scholar Award

MCU-PH at CHU Toulouse, INSERM CERPOP, France

Based on the provided information, Justine Benevent appears to be a strong candidate for the Best Scholar Award. Here is a detailed assessment of her suitability, structured by various criteria:

Education

Justine Benevent’s educational background is distinguished by a series of advanced degrees in pharmacology and related fields. She holds a Diplôme d’état de Docteur en Pharmacie from Bordeaux, providing a comprehensive foundation in pharmacy. She further specialized with a DESC de Pharmacologie médicale from Bordeaux, focusing on medical pharmacology. Her academic journey continued with a Thèse d’Université de Pharmacologie in Toulouse, where she engaged in in-depth research. She also earned a Diplôme Universitaire de pédagogie en Santé from Toulouse, enhancing her skills in health education. Additionally, she completed the DES Pharmacie hospitalière from Bordeaux, highlighting her expertise in hospital pharmacy. These qualifications reflect her extensive training and dedication to the field of pharmacology, underpinning her expertise and contributions to research and clinical practice.

Research Contributions

Justine Benevent has made significant research contributions in pharmacology, with a focus on medications, reproduction, pregnancy, and breastfeeding. She has a solid publication record with 33 papers, including 6 as the first author, and a notable h-index of 10, indicating her research impact and recognition in the academic community.

Geographic Impact

Her research has a wide geographic impact, involving collaborations with international institutions such as PharmaSafe at the University of Oslo, Norway. Her work with the European Consortium IMI ConcePTION highlights her ability to engage in research that transcends national boundaries, addressing health issues relevant to diverse populations.

Collaborative Efforts

Justine Benevent is actively involved in several collaborative research projects and networks. She is a partner of the European Consortium IMI ConcePTION, a member of the national network REGARDs, and participates in various working groups, including those focused on mental health and reproductive risks of drugs. These collaborations demonstrate her commitment to multi-disciplinary and international research efforts.

Applied Research

Her research is highly applied, focusing on real-world health issues such as the effects of medications during pregnancy and breastfeeding. Her role in the project “Maison des Femmes” at CHU de Toulouse, aimed at improving healthcare for women, underscores her dedication to applying research findings to enhance community health and well-being.

Specific Projects and Publications

Justine Benevent has led and contributed to numerous impactful projects. Her work within the “Santé périnatale, pédiatrique et des adolescents” team at CERPOP addresses critical aspects of perinatal and pediatric health. She has also been involved in leading two projects within the IMI ConcePTION consortium, further highlighting her leadership in significant research initiatives.

Environmental Health

While her primary focus is on pharmacology and reproductive health, her work indirectly impacts environmental health by addressing the safe use of medications during critical periods such as pregnancy and breastfeeding. This contributes to overall community health by ensuring safer pharmaceutical practices.

Vector Control

There is no direct mention of research in vector control in her profile. However, her extensive work in pharmacology and drug safety may intersect with public health strategies that could include elements of vector control indirectly.

Waste Management and Water Quality

Justine Benevent’s profile does not indicate direct involvement in waste management and water quality research. Her expertise lies primarily in pharmacology and clinical research methodology.

Parasitology and Infectious Diseases

Although parasitology and infectious diseases are not explicitly mentioned, her pharmacological research, especially in the context of reproductive health, could contribute to understanding and managing infections that affect pregnant women and infants.

Awards and Recognition

Justine Benevent’s academic and research achievements have been recognized through various positions and memberships, such as her role as Treasurer of the CNPM (Collège National de Pharmacologie Médicale) and her involvement in the French Society of Pharmacology and Therapeutics (SFPT). Her significant publication record and citation count further attest to her recognition in the field.

Conclusion

Justine Benevent is a highly accomplished scholar with a strong background in pharmacology, evidenced by her extensive research contributions, collaborative efforts, and applied research impact. Her work addresses crucial health issues related to medications and reproductive health, making her a deserving candidate for the Best Scholar Award. Her leadership in various national and international research projects and her dedication to improving community health through applied research are particularly commendable.

Publications Top Notes

  1. Teaching pharmacovigilance to French medical students during the COVID-19 pandemic: Interest of distance learning clinical reasoning sessions
    • Authors: F. Montastruc, F. Muscari, I. Tack, G. Durrieu, A. Sommet
    • Year: 2024
  2. Adverse perinatal outcomes associated with prenatal exposure to protease-inhibitor-based versus non-nucleoside reverse transcriptase inhibitor-based antiretroviral combinations in pregnant women with HIV infection: A systematic review and meta-analysis
    • Authors: L. Saint-Lary, J. Benevent, C. Damase-Michel, V. Leroy, A. Sommet
    • Year: 2023
    • Citations: 2
  3. Drug monitoring in pregnant women: about the Regards network | Surveillance des médicaments chez les femmes enceintes : à propos du réseau Regards
    • Authors: I. Lacroix, M. Araujo, A. Caillet, L. Delteil, C. Damase-Michel
    • Year: 2023
    • Citations: 1
  4. Risk of Hypertensive Disorders of Pregnancy in Women Treated With Serotonin-Norepinephrine Reuptake Inhibitors: A Comparative Study Using the EFEMERIS Database
    • Authors: J. Benevent, M. Araujo, S. Karki, S. Tebeka, C. Damase-Michel
    • Year: 2023
    • Citations: 2
  5. Adverse drug reactions in pregnant women: Do they differ from those in non-pregnant women of childbearing age?
    • Authors: M. Balon, S. Tessier, C. Damase-Michel, J. Benevent, I. Lacroix
    • Year: 2023
    • Citations: 5
  6. First trimester pregnancy exposure to fosfomycin and risk of major congenital anomaly: a comparative study in the EFEMERIS database
    • Authors: J. Benevent, M. Araujo, A.-B. Beau, I. Lacroix, C. Damase-Michel
    • Year: 2023
    • Citations: 3
  7. Interactions between antiseizure medications and contraception: A study about the knowledge of patients and their specialist physicians
    • Authors: A. Gosset, M. Denuelle, L. Valton, B.énévent, F. Tremollières
    • Year: 2022
    • Citations: 5
  8. Prenatal Drug Exposure in Children With a History of Neuropsychiatric Care: A Nested Case-Control Study
    • Authors: J. Benevent, C. Hurault-Delarue, M. Araujo, I. Lacroix, C. Damase-Michel
    • Year: 2022
  9. What changes in prescription patterns of antiemetic medications in pregnant women in France?
    • Authors: C. Hurault-Delarue, M. Araujo, C. Vabre, C. Damase-Michel, I. Lacroix
    • Year: 2021
    • Citations: 4
  10. Maternal Medication Use and Childhood Cancer in Offspring-Systematic Review and Considerations for Researchers
    • Authors: S. Hjorth, C.H. Hemmingsen, J. Benevent, M. Hargreave, H. Nordeng
    • Year: 2021
    • Citations: 2

 

 

Xin Wang | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Assoc Prof Dr. Xin Wang | Pharmaceutical Science | Best Researcher Award

Assoc. Professor and PhD supervisor of Shanghai Jiao Tong University, China.

Xin Wang is a Tenure-Track Associate Professor at Shanghai Jiao Tong University, specializing in pharmaceutical and biomedical analysis. He earned his Ph.D. in Analytical Chemistry from Peking University and completed postdoctoral work at MIT and UC Berkeley. His research focuses on mass spectrometry, metabolomics, and proteomics, with key projects including drug metabolism analysis, human neurogenesis studies, and advanced sample preparation techniques. Wang’s contributions have garnered several awards, such as the Shanghai Pujiang Talent Plan Award and recognition at MIT. His expertise in analytical techniques and innovative methods has significantly impacted both academic research and industry practices.

Professional Profiles:

Education

Xin Wang completed his B.Sc. in Chemistry at Wuhan University, China, in 2010. He pursued his Ph.D. in Analytical Chemistry at Peking University, graduating in 2015. Following his doctoral studies, Dr. Wang undertook postdoctoral research at the Massachusetts Institute of Technology (MIT) from 2015 to 2018. Since 2020, he has been serving as a Tenure-Track Associate Professor at the School of Pharmaceutical Sciences, Shanghai Jiao Tong University, China.

Professional Experience

Xin Wang’s professional experience includes a significant role as a Tenure-Track Associate Professor at the School of Pharmaceutical Sciences, Shanghai Jiao Tong University, where he has been since 2020. Before this, he was a Senior Postdoctoral Associate at MIT’s Department of Biological Engineering from 2018 to 2019, and a Postdoctoral Associate in the same department from 2015 to 2018. His earlier academic journey includes a Ph.D. in Analytical Chemistry from Peking University, where he also worked as a Visiting Graduate Student at UC Berkeley.

Research Interest

Xin Wang’s research interests are at the forefront of pharmaceutical and biomedical analysis, emphasizing the use of advanced analytical techniques. His work primarily focuses on mass spectrometry and its applications in drug metabolism and toxicity testing, aiming to replace traditional trials with in vitro human systems. He is also deeply engaged in metabolomics and proteomics, using these techniques to unravel metabolic features in human neurogenesis and other physiological processes. Wang has developed innovative methods in solid-phase microextraction to enhance the sensitivity and accuracy of analyzing low-molecular-mass compounds. His research integrates these areas to advance understanding in drug testing, biomarker discovery, and the mechanistic insights into human health and disease. This multidisciplinary approach not only pushes the boundaries of analytical chemistry but also contributes to more effective and efficient drug development and disease treatment strategies.

Award and Honors

Xin Wang has received several prestigious awards and honors throughout his career. In 2023, he was recognized as an Outstanding Individual with Exceptional Contributions in Education by the School of Pharmacy at Shanghai Jiao Tong University. He also won the Second Prize in the Young Professor Teaching Skills Competition at Shanghai Jiao Tong University in 2022. Wang’s accolades include the Shanghai Overseas High-Level Talent Program Award and the Shanghai Pujiang Talent Plan Award, both in 2020. In 2016, he earned First Place in the MIT Center for Environmental Health Sciences Session. Additionally, he was awarded the First Prize in the Science and Technology Award from the China Association for Instrumental Analysis in 2015. Earlier achievements include the Aoqing Tang Scholarship (2015), the Brilliance Scholarship (2014), and multiple awards for his graduate research and innovation.

Research Skills

Xin Wang possesses advanced research skills in several key areas of analytical and biomedical science. His expertise includes pharmaceutical and biomedical analysis, utilizing techniques such as mass spectrometry, metabolomics, and proteomics to study complex biological systems. He is proficient in solid-phase microextraction and has developed innovative methods for capturing and quantifying low-molecular-mass compounds. Wang’s work with time-dependent metabolomics and LC-MS-based quantitation reflects his ability to apply cutting-edge analytical techniques to understand human neurogenesis and drug metabolism. His research in automated sample preparation and ambient mass spectrometry demonstrates his skills in developing novel methodologies for high-sensitivity detection and analysis. Wang’s contributions to bioanalytical strategies and experimental design have been recognized and published in top scientific journals, showcasing his ability to push the boundaries of current research methodologies.

Publications

  1. “Mass spectrometry‐based metabolomics for the investigation of antibiotic–bacterial interactions”
    • Authors: Xin Wang
    • Year: 2024
  2. “A new approach towards highly sensitive detection of endogenous N-acetylaspartic acid, N-acetylglutamic acid, and N-acetylaspartylglutamic acid in brain tissues based on strong anion exchange monolith microextraction coupled with UHPLC-MS/MS”
    • Authors: Xin Wang
    • Year: 2024
  3. “Mass spectrometry-based quantitation combined with time-dependent metabolomics to discover metabolic features in human neurogenesis using neural constructs generated from neural progenitor cells”
    • Authors: Xin Wang
    • Year: 2023
  4. “Mass spectrometry analysis of S-nitrosylation of proteins and its role in cancer, cardiovascular and neurodegenerative diseases”
    • Authors: Xin Wang
    • Year: 2022
  5. “Low Doses of Arsenic in a Mouse Model of Human Exposure and in Neuronal Culture Lead to S-Nitrosylation of Synaptic Proteins and Apoptosis via Nitric Oxide”
    • Authors: Xin Wang
    • Year: 2020
  6. “Analysis of an Integrated Human Multiorgan Microphysiological System for Combined Tolcapone Metabolism and Brain Metabolomics”
    • Authors: Xin Wang
    • Year: 2019
  7. “Automated Online Solid-Phase Derivatization for Sensitive Quantification of Endogenous S-Nitrosoglutathione and Rapid Capture of Other Low-Molecular-Mass S-Nitrosothiols”
    • Authors: Xin Wang
    • Year: 2018
  8. “Shank3 mutation in a mouse model of autism leads to changes in the S-nitroso-proteome and affects key proteins involved in vesicle release and synaptic function”
    • Authors: Xin Wang
    • Year: 2018
  9. “Fast analysis of glycosides based on HKUST-1-coated monolith solid-phase microextraction and direct analysis in real-time mass spectrometry”
    • Authors: Xin Wang
    • Year: 2017
  10. “Polymer‐based monolithic column with incorporated chiral metal–organic framework for enantioseparation of methyl phenyl sulfoxide using nano‐liquid chromatography”
    • Authors: Xin Wang
    • Year: 2016

 

Taigang Liang | Drug Design | Best Researcher Award

Posted on by ScienceFather

Prof. Taigang Liang | Drug Design | Best Researcher Award

Professor at School of Pharmacy/Shanxi Medical University, China.

Prof. Tai Gang Liang excels in drug synthesis, focusing on developing novel pharmaceutical compounds. His research spans drug action mechanisms, where he explores how drugs interact with biological systems to produce therapeutic effects. Liang is skilled in computer-aided drug design, using computational tools to optimize drug candidates efficiently. He also integrates Traditional Chinese Medicine (TCM) with modern scientific methods to advance drug development and industrialization. His expertise extends to biological evaluation techniques, sustainable synthesis, and analytical methods, ensuring comprehensive assessments of drug efficacy and safety. Prof. Liang’s innovative approaches contribute significantly to enhancing drug discovery and development processes. 🧪🔬💻

Professional Profiles:

Education

Prof. Tai Gang Liang, a distinguished scientist at Shanxi Medical University’s School of Pharmacy, has a robust educational background in pharmaceutical sciences. He earned his Doctor of Philosophy (PhD) in 2011, Master of Science (MS) in 2003, and Bachelor of Science (BS) in 2000, all from Shanxi Medical University. His extensive expertise spans drug synthesis, drug action mechanisms, computer-aided drug design, and the industrialization of traditional Chinese medicine (TCM). Prof. Liang’s research is recognized for its contributions to both the development of novel drug compounds and innovative drug design methodologies. His academic journey reflects a deep commitment to advancing pharmaceutical sciences and addressing global health challenges through cutting-edge research.

Professional Experience

Prof. Tai Gang Liang is a distinguished scientist at the School of Pharmacy, Shanxi Medical University, with extensive expertise in drug synthesis, drug action mechanisms, and computer-aided drug design. His research also focuses on the industrialization of traditional Chinese medicine (TCM). Over his career, Prof. Liang has received several prestigious awards, including being named a Shanxi Province Outstanding Young Scholar and a member of the Shanxi Province “131 Leading Talent Engineering.” He also earned the Silver Prize at the 12th “Challenge Cup” China College Entrepreneurship Plan Competition. His work has made significant contributions to advancing pharmaceutical sciences and TCM research, reflecting his dedication to innovation and excellence in the field.

 Research Interest

Prof. Tai Gang Liang’s research interests encompass a broad spectrum within pharmaceutical sciences. His primary focus includes drug synthesis and drug action mechanisms, where he aims to develop novel therapeutic agents and understand their biological effects. He is also deeply involved in computer-aided drug design, utilizing computational tools to optimize drug development processes. Additionally, Prof. Liang investigates the industrialization of traditional Chinese medicine (TCM), striving to integrate traditional practices with modern scientific techniques to enhance the efficacy and application of TCM therapies. His research aims to bridge the gap between traditional and modern medicinal approaches, advancing both fields through innovative solutions and interdisciplinary collaboration.

Award and Honors

Prof. Tai Gang Liang has received several notable awards and honors in recognition of his contributions to the field of pharmaceutical sciences. He was named a Shanxi Province Outstanding Young Scholar, highlighting his exceptional achievements and potential in his research domain. He is also a member of the Shanxi Province “131 Leading Talent Engineering”, an accolade given to influential professionals in the province. Additionally, Prof. Liang was awarded the Silver Prize at the 12th “Challenge Cup” China College Entrepreneurship Plan Competition, reflecting his innovative approach and entrepreneurial spirit in scientific endeavors. These accolades underscore his dedication and significant impact in drug development and traditional Chinese medicine. 🏆🌟

 Research Skills

Prof. Tai Gang Liang excels in drug synthesis, focusing on developing novel pharmaceutical compounds. His research spans drug action mechanisms, where he explores how drugs interact with biological systems to produce therapeutic effects. Liang is skilled in computer-aided drug design, using computational tools to optimize drug candidates efficiently. He also integrates Traditional Chinese Medicine (TCM) with modern scientific methods to advance drug development and industrialization. His expertise extends to biological evaluation techniques, sustainable synthesis, and analytical methods, ensuring comprehensive assessments of drug efficacy and safety. Prof. Liang’s innovative approaches contribute significantly to enhancing drug discovery and development processes. 🧪🔬💻

Publications
  1. Green synthesis of selenium nanoparticles with extract of hawthorn fruit induced HepG2 cells apoptosis
    • Authors: D Cui, T Liang, L Sun, L Meng, C Yang, L Wang, T Liang, Q Li
    • Year: 2018
    • Citations: 112
  2. Comparison of the Phenolic Content and Antioxidant Activities of Apocynum venetum L. (Luo-Bu-Ma) and Two of Its Alternative Species
    • Authors: T Liang, W Yue, Q Li
    • Year: 2010
    • Citations: 107
  3. Selenium nanoparticles fabricated in laminarin polysaccharides solutions exert their cytotoxicities in HepG2 cells by inhibiting autophagy and promoting apoptosis
    • Authors: D Cui, J Ma, T Liang, L Sun, L Meng, T Liang, Q Li
    • Year: 2019
    • Citations: 93
  4. Synthesis, characterization and antitumor properties of selenium nanoparticles coupling with ferulic acid
    • Authors: D Cui, C Yan, J Miao, X Zhang, J Chen, L Sun, L Meng, T Liang, Q Li
    • Year: 2018
    • Citations: 78
  5. Chemopreventive Effects of Peucedanum praeruptorum DUNN and Its Major Constituents on SGC7901 Gastric Cancer Cells
    • Authors: T Liang, W Yue, Q Li
    • Year: 2010
    • Citations: 51
  6. Farrerol Directly Targets GSK‐3β to Activate Nrf2‐ARE Pathway and Protect EA.hy926 Cells against Oxidative Stress‐Induced Injuries
    • Authors: C Yan, X Zhang, J Miao, H Yuan, E Liu, T Liang, Q Li
    • Year: 2020
    • Citations: 37
  7. Apoptosis induced by farrerol in human gastric cancer SGC-7901 cells through the mitochondrial-mediated pathway
    • Authors: E Liu, T Liang, X Wang, S Ban, L Han, Q Li
    • Year: 2015
    • Citations: 35
  8. Diorganotin (IV) complexes with 4-nitro-N-phthaloyl-glycine: Synthesis, characterization, antitumor activity and DNA-binding studies
    • Authors: C Yan, J Zhang, T Liang, Q Li
    • Year: 2015
    • Citations: 35
  9. Relaxation of rat aorta by farrerol correlates with potency to reduce intracellular calcium of VSMCs
    • Authors: X Qin, X Hou, M Zhang, T Liang, J Zhi, L Han, Q Li
    • Year: 2014
    • Citations: 31
  10. Sustained ERK activation-mediated proliferation inhibition of farrerol on human gastric carcinoma cell line by G0/G1-phase cell-cycle arrest
    • Authors: E Liu, J Li, S Shi, X Wang, T Liang, B Wu, Q Li
    • Year: 2016
    • Citations: 26